Treatment with Non-specific HDAC Inhibitors Administered after Disease Onset does not Delay Evolution in a Mouse Model of Progressive Multiple Sclerosis.

Buonvicino, Daniela; Ranieri, Giuseppe; Chiarugi, Alberto

Buonvicino, Daniela; Ranieri, Giuseppe; Chiarugi, Alberto.

Afiliação

Buonvicino D; Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Florence, Italy. Electronic address: daniela.buonvicino@unifi.it.
Ranieri G; Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Florence, Italy.
Chiarugi A; Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Florence, Italy.

Neuroscience ; 465: 38-45, 2021 06 15.

Article em En | MEDLINE | ID: mdl-33862148

Assuntos

Encefalomielite Autoimune Experimental; Esclerose Múltipla; Animais; Encefalomielite Autoimune Experimental/tratamento farmacológico; Inibidores de Histona Desacetilases/farmacologia; Camundongos; Camundongos Endogâmicos C57BL; Camundongos Endogâmicos NOD; Esclerose Múltipla/tratamento farmacológico; Glicoproteína Mielina-Oligodendrócito; Fragmentos de Peptídeos

Palavras-chave

HDAC inhibitor; entinostat; givinostat; panobinostat; progressive EAE

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Encefalomielite Autoimune Experimental / Esclerose Múltipla Tipo de estudo: Guideline / Prognostic_studies Limite: Animals Idioma: En Revista: Neuroscience Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google